Titan Total Stockholder Equity from 2010 to 2024
| TTNP Stock | USD 3.96 0.32 8.79% |
Total Stockholder Equity | First Reported 1995-12-31 | Previous Quarter 6.6 M | Current Value 4 M | Quarterly Volatility 30.7 M |
Check Titan Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Titan Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 106.4 K, Interest Expense of 31.7 K or Total Revenue of 174.8 K, as well as many indicators such as Price To Sales Ratio of 32.03, Dividend Yield of 0.0015 or PTB Ratio of 0.89. Titan financial statements analysis is a perfect complement when working with Titan Pharmaceuticals Valuation or Volatility modules.
Titan | Total Stockholder Equity |
Latest Titan Pharmaceuticals' Total Stockholder Equity Growth Pattern
Below is the plot of the Total Stockholder Equity of Titan Pharmaceuticals over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Titan Pharmaceuticals' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Titan Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Total Stockholder Equity | 10 Years Trend |
|
Total Stockholder Equity |
| Timeline |
Titan Total Stockholder Equity Regression Statistics
| Arithmetic Mean | 1,176,727 | |
| Coefficient Of Variation | 866.42 | |
| Mean Deviation | 7,047,588 | |
| Median | 5,138,000 | |
| Standard Deviation | 10,195,388 | |
| Sample Variance | 103.9T | |
| Range | 36.3M | |
| R-Value | 0.52 | |
| Mean Square Error | 81.6T | |
| R-Squared | 0.27 | |
| Significance | 0.05 | |
| Slope | 1,186,969 | |
| Total Sum of Squares | 1455.2T |
Titan Total Stockholder Equity History
About Titan Pharmaceuticals Financial Statements
Titan Pharmaceuticals shareholders use historical fundamental indicators, such as Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Titan Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Titan Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Titan Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Stockholder Equity | 6.6 M | 6.3 M |
Pair Trading with Titan Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Titan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Titan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Titan Stock
| 0.89 | ETON | Eton Pharmaceuticals Downward Rally | PairCorr |
| 0.88 | VRNA | Verona Pharma PLC | PairCorr |
| 0.82 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.81 | ELDN | Eledon Pharmaceuticals | PairCorr |
| 0.46 | DSGN | Design Therapeutics | PairCorr |
The ability to find closely correlated positions to Titan Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Titan Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Titan Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Titan Pharmaceuticals to buy it.
The correlation of Titan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Titan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Titan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Titan Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Titan Stock Analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.